Anipamil

Drug Profile

Anipamil

Alternative Names: LU 42668

Latest Information Update: 24 Jan 2013

Price : $50

At a glance

  • Originator Abbott GmbH & Co. KG
  • Class Antiarrhythmics; Antihypertensives
  • Mechanism of Action Calcium channel antagonists; LDL receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Arrhythmias; Atherosclerosis; Hyperlipidaemia; Hypertension; Ischaemic heart disorders

Most Recent Events

  • 29 Apr 1996 Discontinued-III for Hypertension in Germany (PO)
  • 29 Apr 1996 Discontinued-III for Ischaemic heart disorders (Unknown route)
  • 29 Apr 1996 Discontinued-III for Ischaemic heart disorders in Uganda (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top